Resources

Shigella is the leading bacterial cause of childhood diarrhea, and infections can have long-term effects on growth and development. No licensed Shigella vaccines currently exist, but several promising candidates in development could become available in a few years. PATH conducted a series of studies to better understand the public health value of potential Shigella vaccines and help inform decisions by international agencies, funders, vaccine developers, and national policymakers. As part of this work, PATH supported the development of two vaccine impact models to estimate the effects of reducing not only Shigella diarrhea but also Shigella-attributable stunting. One model measures cost-effectiveness based on health outcomes, and the other measures the long-term societal economic benefit of reducing stunting, focusing on its impact on future wages and productivity. This fact sheet provides an overview of the results.

Shigella is the leading bacterial cause of childhood diarrhea, and infections can have long-term effects on growth and development. No licensed Shigella vaccines currently exist, but several promising candidates in development could become available in a few years. PATH conducted a series of studies to better understand the public health value of potential Shigella vaccines and help inform decisions by international agencies, funders, vaccine developers, and national policymakers. This included a multi-country feasibility and acceptability study with national stakeholders and healthcare providers in Burkina Faso, Ghana, Kenya, Nepal, and Vietnam to identify preferences and priorities for future Shigella vaccines. These briefs provide an overview of the results in each of the study countries.

The Partnership for Vivax Elimination (PAVE) led by PATH and Medicines for Malaria Venture (MMV) brings together National Malaria Programs (NMPs), researchers, funders, and other organizations to support countries as they strive to achieve their elimination goals through:▪ Working with NMPs to identify optimal radical cure tools and strategies for their given contexts.▪ Generating and sharing high-quality evidence on Plasmodium vivax (P. vivax) case management to inform policy decisions and implementation by national governments▪ Advancing the development and availability of quality-assured medicines and diagnostics for P. vivax.

For over 30 years the PATH Diagnostics program has collaborated with partners across the full diagnostics ecosystem to develop and commercialize appropriate, affordable, quality-assured diagnostics that improve health outcomes of people and communities in low-resource settings.

PATH hosted the 2022 Vaccines Against Shigella and ETEC (VASE) Conference on November 29 to December 1, 2022, in Washington, DC. This international event shared cutting-edge research related to the development of vaccines against neglected diarrheal pathogens including Shigella, enterotoxigenic Escherichia coli (ETEC), Campylobacter, and non-typhoidal Salmonella. PATH received 139 abstracts for consideration in the scientific content of the meeting, and the final conference program featured 24 abstract-based oral presentations and 87 abstract-based poster presentations. This booklet provides the complete abstracts for all oral and poster presentations at VASE 2022.